Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268819 | 0.90 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL4207867 | 0.88 | HDAC1 (0.57) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL671194 | 0.86 | REN (0.55) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL28741972 | 0.86 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL27754647 | 0.86 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL8615545 | 0.86 | LIMK2 (0.63) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL678725 | 0.86 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| Diphenylmethane SCHEMBL8928167 | 0.86 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL4508037 | 0.85 | LMNA (0.56) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL16333819 | 0.85 | REN (0.54) | L3MBTL1ALDH1A1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | claimed |
| EP-3424939-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2669290-A1 | Nucleic Acid Chemical Modifications | Alnylam Pharmaceuticals Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2004024082-A2 | HIGHLY SPECIFIC MODULATORS OF GTPASES FOR TARGET VALIDATION | IRM, LLC (GB) | 2004-03-25 | — | — | WO | disclosed |
| US-6288141-B1 | Ink compositions | XEROX CORPORATION | 2001-09-11 | — | — | US | disclosed |
| US-6187082-B1 | COMPOSITION COMPRISED OF THIOUREA AND INK CARBAMATE, EACH WITH SPECIFIED MELTING POINT AND ACOUSTIC-LOSS VALUE, LIGHTFASTNESS COMPONENT, LIGHTFAST ANTIOXIDANT, COLORANT | XEROX CORPORATION | 2001-02-13 | — | — | US | disclosed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| CN-1234023-A | 4-aminoethoxy indoes as dopamin D2 agonists and as 5HT1A ligands | AMERICAN HOME PROD (US) | 1999-11-03 | — | — | CN | disclosed |
| CN-1234024-A | 4-aminoethoxy indolone derivatives | AMERICAN HOME PROD (US) | 1999-11-03 | — | — | CN | disclosed |
| EP-0017772-B1 | METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY | BAYER AG (DE) | 1982-07-28 | — | — | EP | disclosed |
| EP-0014263-B1 | METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY | BAYER AG (DE) | 1982-05-05 | — | — | EP | disclosed |
| EP-0017772-A1 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
| EP-0014263-A2 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | L3MBTL1 508/4885ALDH1A1 1390/4885HDAC3 3380/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | L3MBTL1 2363/4885ALDH1A1 466/4885HDAC3 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.